Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Reckitt Benckiser Group's other long-term liabilities for the quarter that ended in Jun. 2026 was £2,852 Mil.
Reckitt Benckiser Group's quarterly other long-term liabilities
declined
from Jun. 2025 (£2,900 Mil) to Dec. 2025 (£2,742 Mil) but then
increased
from Dec. 2025 (£2,742 Mil) to Jun. 2026 (£2,852 Mil).
Reckitt Benckiser Group's annual other long-term liabilities
declined
from Dec. 2023 (£3,165 Mil) to Dec. 2024 (£3,108 Mil) and
declined
from Dec. 2024 (£3,108 Mil) to Dec. 2025 (£2,742 Mil).
Reckitt Benckiser Group Other Long-Term Liabilities Related Terms
Reckitt Benckiser Group Other Long-Term Liabilities Historical Data
* Premium members only.
The historical data trend for Reckitt Benckiser Group's Other Long-Term Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reckitt Benckiser Group Other Long-Term Liabilities Chart
Reckitt Benckiser Group Other Long-Term Liabilities Calculation
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
What does a Other Long-Term Liabilities of £2,852 Mil mean?
Reckitt Benckiser Group (CHIX:RKTL) has a Other Long-Term Liabilities of £2,852 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Reckitt Benckiser Group and its competitors.
Is Reckitt Benckiser Group's Other Long-Term Liabilities too high?
Reckitt Benckiser Group's current Other Long-Term Liabilities is £2,852 Mil. Overall, Reckitt Benckiser Group has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Reckitt Benckiser Group's Other Long-Term Liabilities compare to PG and CL?
Reckitt Benckiser Group's Other Long-Term Liabilities of £2,852 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Consumer Packaged Goods company?
A good Other Long-Term Liabilities depends on the Consumer Packaged Goods industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Reckitt Benckiser Group and its competitors. Reckitt Benckiser Group's current Other Long-Term Liabilities is £2,852 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reckitt Benckiser Group stock overvalued right now?
Based on GuruFocus' analysis, Reckitt Benckiser Group (CHIX:RKTL) is currently considered Fairly Valued. The stock's GF Value™ is £51.70, compared to a current price of £51.48 — trading 0.4% below its estimated fair value. The current Other Long-Term Liabilities is £2,852 Mil. Reckitt Benckiser Group's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Reckitt Benckiser Group (CHIX:RKTL), the current Other Long-Term Liabilities is £2,852 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Reckitt Benckiser Group (CHIX:RKTL) Overvalued in 2026?
Based on GuruFocus' analysis, Reckitt Benckiser Group stock appears to be undervalued.
The current stock price of £51.48 is trading 0.4% below its estimated GF Value™ of £51.70.
GuruFocus considers Reckitt Benckiser Group to be Fairly Valued.
Key valuation signals for CHIX:RKTL:
Other Long-Term Liabilities: £2,852 Mil
GF Value™: £51.70 vs. price of £51.48 (0.4% below fair value)
No single metric tells the full story. See the CHIX:RKTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Reckitt Benckiser was formed in 1999 through the merger of the British firm Reckitt & Colman and Dutch-based Benckiser. Recently rebranded under the corporate name Reckitt, it sells a portfolio that includes a variety of household and consumer health brands, such as Lysol, Finish, Durex, and Mucinex, many of which hold a number-one or number-two position in their categories globally. Reckitt has repositioned its portfolio and has entered the infant formula market through the acquisition of Mead Johnson in 2017, expanded its consumer health presence by acquiring Schiff Nutrition, K-Y, and Biofreeze, and has exited the food industry. The firm operates in 60 countries and sells products in more than 200, generating over 40% of core sales from emerging markets.
70GF Score
Get the complete analysis for CHIX:RKTL
Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RKTL has been successfully added to your 
